Evidence map›Paper›PMID 31428741›Full record

ReviewVaccine: X2019

The costs of delivering vaccines in low- and middle-income countries: Findings from a systematic review.

Kelsey Vaughan, Annette Ozaltin, Michaela Mallow, Flavia Moi, Colby Wilkason, Juliana Stone, Logan Brenzel

Abstract readReview
In one paragraph

Review in Vaccine: X, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Economic burden of measles outbreaks: a cost-of-illness study in a middle-income country in the post-elimination era.Revista panamericana de salud publica = Pan American journal of public health · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kelsey VaughanThinkWell, 1875 Connecticut Avenue, 10th Floor, Washington, DC 20009, USA.
Annette OzaltinThinkWell, 1875 Connecticut Avenue, 10th Floor, Washington, DC 20009, USA.
Michaela MallowThinkWell, 1875 Connecticut Avenue, 10th Floor, Washington, DC 20009, USA.
Flavia MoiThinkWell, 1875 Connecticut Avenue, 10th Floor, Washington, DC 20009, USA.
Colby WilkasonThinkWell, 1875 Connecticut Avenue, 10th Floor, Washington, DC 20009, USA.
Juliana StoneThinkWell, 1875 Connecticut Avenue, 10th Floor, Washington, DC 20009, USA.
Logan BrenzelBill & Melinda Gates Foundation, 440 5th Ave N., Seattle, WA 98109, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInformation on immunization delivery costs (IDCs) is essential for better planning and budgeting for the sustainability and performance of national programs. However, delivery cost evidence is fragmented and of variable quality, making it difficult for policymakers, planners, and other stakeholders to understand and use. This study aimed to consolidate and summarize the evidence on delivery costs, answering the question: What are the unit costs of vaccine delivery across low- and middle-income countries (LMICs) and through a variety of delivery strategies?

methodsWe conducted a systematic review of over 15,000 published and unpublished resources from 2005 to 2018 that included IDCs in LMICs. We quality-rated and extracted data from 61 resources that contained 410 immunization delivery unit costs (e.g., cost per dose, cost per fully immunized child). We converted cost findings to a common year (2016) and currency (U.S. dollars) to ensure comparability across studies and settings. We performed a descriptive and gap analysis and developed immunization delivery cost ranges using comparable unit costs for single vaccines and schedules of vaccines.

resultsThe majority of IDC evidence comes from low-income countries and Sub-Saharan Africa. Most unit costs are presented as cost per dose and represent health facility-based delivery. DISCUSSION: The cost ranges may be higher than current estimates used in many LMICs for budgeting: $0.16-$2.54 incremental cost per dose (including economic, financial, and fiscal costs) for single, newly introduced vaccines, and $0.75-$9.45 full cost per dose (economic costs) for schedules of four to eight vaccines delivered to children under one.

conclusionsDespite increased attention on improving coverage and strengthening immunization delivery, evidence on the cost of delivery is nascent but growing. The cost ranges can inform planning and policymaking, but should be used with caution given their width and the few unit costs used in their development.

Indexed as

Costs and cost analysisImmunization deliveryImmunization financingLow- and middle-income countriesSystematic reviewVaccines

Identifiers

PMID31428741
PMCPMC6697256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.